CABA vs RLTY Comparison

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Cohen & Steers Real Estate Opportunities and Income Fund is a non-diversified, closed-end management statutory trust. Its primary investment objective is high current income. Its secondary investment objective is capital appreciation. The fund invests the majority of its managed assets in real estate-related investments and preferred and other income securities.